OBIO — Orchestra BioMed Holdings, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1814114 ·
Last close
$6.97
Market Cap
$548.57M
52W High
$7.45
52W Low
$3.46
ADV30
472,235
Next earnings
2026-11-10
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 91,000 63,000 -23,296,000 -18,750,000 107,736,000 27,761,000 99,954,000
Jun 2026 88,000 63,000 -22,356,000 -23,755,000 115,700,000 20,472,000 96,377,000
Mar 2026 110,000 78,000 -22,076,000 -20,691,000 100,658,000 28,367,000 59,466,000
Dec 2025 30,917,000 30,866,000 6,754,000 6,245,000 114,857,000 34,690,000 61,287,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,308,000
Investing CF
$-9,738,000
Financing CF
$58,795,000
CapEx
$-869,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-425,775,000
Inventory
$221,000
Receivables
$56,000
ST Investments
$74,146,000
EBIT TTM
$-53,711,000
Pretax Income TTM
$-56,951,000
Interest Exp TTM
$2,978,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$31,206,000
EBITDA
$-60,605,000
Free Cash Flow
$-37,931,752
Enterprise Value
$553,211,968
Total Cash
$101,907,000
Total Debt
$73,544,000
Shares Out
78,704,957
Trailing EPS
$-0.75
Book Value
$0.13
ROE
-182.3%
ROA
-35.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 33,482,000 -51,807,000 -52,701,000 114,857,000 61,287,000 53,570,000 -48,963,000
Dec 2024 2,638,000 -64,301,000 -61,024,000 76,173,000 43,215,000 32,958,000 -50,558,000
Dec 2023 2,760,000 -51,506,000 -49,120,000 95,212,000 27,169,000 68,043,000 -46,127,000
Dec 2022 3,533,000 -32,657,000 -33,608,000 95,572,000 43,038,000 52,534,000 -29,289,000

TTM Snapshot

Revenues TTM
$31,976,000
NetIncome TTM
$-59,029,000
OpCashFlow TTM
—
Assets (Latest)
$115,700,000
Forward EPS
$-1.41

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $7.46 · call volume: 189 · put volume: 1
Expected Move to 2026-12-18: ±$1.30 (17.43%) — implied range $6.16 – $8.76 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AVHHL AVITA Medical, Inc. $549.85M $3.50 —
AVR Anteris Technologies Global Corp. $518.67M $5.32 —
SGHT Sight Sciences, Inc. $583.02M $10.49 —
TCMD TACTILE SYSTEMS TECHNOLOGY INC $583.56M $26.05 —
RCEL AVITA Medical, Inc. $495.50M $15.77 —

News headlines (Yahoo Finance, 1h cache)

Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
2026-11-17 13:30 · Yahoo
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
2026-11-16 13:55 · Yahoo
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
2026-11-10 22:40 · Yahoo
Orchestra BioMed Announces Pricing of Public Offering
2026-11-06 03:42 · Yahoo
Orchestra BioMed Announces Proposed Public Offering
2026-11-05 21:01 · Yahoo
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
2026-10-29 12:30 · Yahoo
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
2026-10-22 12:30 · Yahoo
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
2026-10-01 12:00 · Yahoo
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
2026-09-21 11:33 · Yahoo
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-27 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.